– Trial to be conducted at University of Washington, led by Dr. Anthony Back – TORONTO–(BUSINESS WIRE)–Cybin Inc. (NEO:CYBN) (NYSE American:CYBN) (“ Cybin” or the “Company”), a biopharmaceutical company focused on progressing “Psychedelics to Therapeutics”, today announced that the U.S. Food and Drug Administration (“FDA”) has authorized an investigator-initiated randomized…


Previous articlePT275 – James Fadiman, Ph.D. – Transpersonal Psychology, Microdosing, and Your Symphony of Selves
Next articleIbogaine and Cardiac Arrhythmia: The Heart of the Matter